These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Celecoxib and Pioglitazone as Potential Therapeutics for Regulating TGF-β-Induced Hyaluronan in Dysthyroid Myopathy. Cheng AM; Yin HY; Chen A; Liu YW; Chuang MC; He H; Tighe S; Sheha H; Liao SL Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1951-9. PubMed ID: 27092721 [TBL] [Abstract][Full Text] [Related]
67. Effects of peroxisome proliferator-activated receptor-γ activation on apoptosis in rats with acute pancreatitis. Xu P; Lou XL; Chen C; Yang ZW Dig Dis Sci; 2013 Dec; 58(12):3516-23. PubMed ID: 24185678 [TBL] [Abstract][Full Text] [Related]
68. MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX. Nadarajan K; Balaram P; Khoo BY Cytotechnology; 2016 Oct; 68(5):1771-87. PubMed ID: 26754842 [TBL] [Abstract][Full Text] [Related]
69. Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell. Xiao J; Chen W; Lu Y; Zhang X; Fu C; Yan Z; Zhang Z; Ye Z Inflamm Res; 2015 Aug; 64(8):603-14. PubMed ID: 26072064 [TBL] [Abstract][Full Text] [Related]
70. Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4. Wassef MAE; Tork OM; Rashed LA; Ibrahim W; Morsi H; Rabie DMM Exp Clin Endocrinol Diabetes; 2018 Jan; 126(1):27-38. PubMed ID: 28449155 [TBL] [Abstract][Full Text] [Related]
71. Pioglitazone Use and Risk of Bladder Cancer: an Yang SL; Wang JJ; Chen M; Xu L; Li N; Luo YL; Bu L; Zhang MN; Li H; Su BL Int J Med Sci; 2018; 15(3):228-237. PubMed ID: 29483814 [No Abstract] [Full Text] [Related]
72. Anticonvulsant and ameliorative effects of pioglitazone on cognitive deficits, inflammation and apoptosis in the hippocampus of rat pups exposed to febrile seizure. Hussein HA; Moghimi A; Roohbakhsh A Iran J Basic Med Sci; 2019 Mar; 22(3):267-276. PubMed ID: 31156787 [TBL] [Abstract][Full Text] [Related]
73. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Ren L; Liu N; Zhi H; Li Y; Li Y; Tang R; Sheng Z Cardiovasc Diabetol; 2011 Jan; 10():10. PubMed ID: 21269478 [TBL] [Abstract][Full Text] [Related]
75. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis. Koufany M; Jouzeau JY; Moulin D Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921 [TBL] [Abstract][Full Text] [Related]
77. A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma. Nishikawa S; Tanaka A; Matsuda A; Oida K; Jang H; Jung K; Amagai Y; Ahn G; Okamoto N; Ishizaka S; Matsuda H Cancer Med; 2014 Apr; 3(2):416-25. PubMed ID: 24510578 [TBL] [Abstract][Full Text] [Related]
78. Ligand-activated peroxisome proliferator-activated receptor-δ and -γ inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1. Hwang JS; Lee WJ; Kang ES; Ham SA; Yoo T; Paek KS; Lim DS; Do JT; Seo HG Cell Death Dis; 2014 Oct; 5(10):e1432. PubMed ID: 25275593 [TBL] [Abstract][Full Text] [Related]
79. Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis. Zhang Y; Li X; Fang S; Zhu Z; Yao M; Ying L; Zhu L; Ma Z; Wang W Mol Med Rep; 2017 Aug; 16(2):1793-1800. PubMed ID: 28656266 [TBL] [Abstract][Full Text] [Related]
80. [PPAR-γ agonist inhibits the expressions of chemokines induced by IFN-γ and TNF-α in renal tubular epithelial cells]. Song Y; Lin Q; Zheng J; Zhu X; Yang S Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):673-6. PubMed ID: 25001926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]